U.S. markets open in 3 hours 22 minutes
  • S&P Futures

    4,322.75
    -18.75 (-0.43%)
     
  • Dow Futures

    33,921.00
    -134.00 (-0.39%)
     
  • Nasdaq Futures

    14,080.50
    -78.00 (-0.55%)
     
  • Russell 2000 Futures

    1,956.90
    -15.80 (-0.80%)
     
  • Crude Oil

    87.31
    -0.04 (-0.05%)
     
  • Gold

    1,811.00
    -18.70 (-1.02%)
     
  • Silver

    23.22
    -0.59 (-2.49%)
     
  • EUR/USD

    1.1191
    -0.0054 (-0.48%)
     
  • 10-Yr Bond

    1.8480
    0.0000 (0.00%)
     
  • Vix

    31.15
    -0.01 (-0.03%)
     
  • GBP/USD

    1.3402
    -0.0060 (-0.45%)
     
  • USD/JPY

    115.2120
    +0.5520 (+0.48%)
     
  • BTC-USD

    36,407.55
    -1,495.98 (-3.95%)
     
  • CMC Crypto 200

    829.61
    -26.20 (-3.06%)
     
  • FTSE 100

    7,494.13
    +24.35 (+0.33%)
     
  • Nikkei 225

    26,170.30
    -841.03 (-3.11%)
     

MacroGenics (MGNX) Stock Jumps 8.9%: Will It Continue to Soar?

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • MGNX

MacroGenics MGNX shares ended the last trading session 8.9% higher at $23. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 14.5% loss over the past four weeks.

MacroGenics recorded a strong price increase following the previous day’s nearly 3% setback when the final overall survival (OS) results from the SOPHIA study was released. The OS analysis of the SOPHIA Phase 3 study did not demonstrate a statistically significant advantage for MacroGenics’ FDA-authorized breast cancer treatment MARGENZA over Roche’s trastuzumab, when combined with chemotherapy respectively. However, a delayed upturn in the market sentiment can be attributed to a pre-specified, non-alpha-allocated exploratory analysis assessing the effect of CD16A allelic variation on MARGENZA activity. The analysis demonstrated a 2.5 months prolonged median OS in the MARGENZA arm compared to the trastuzumab arm. Additionally, the safety profile of MARGENZA was said to be similar to what had previously been reported and to be in line with the product's existing FDA-approved label.

Price and Consensus

Price Consensus Chart for MGNX
Price Consensus Chart for MGNX

This biopharmaceutical company is expected to post quarterly loss of $0.63 per share in its upcoming report, which represents a year-over-year change of +4.6%. Revenues are expected to be $39.56 million, up 116.8% from the year-ago quarter.

Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.

For MacroGenics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on MGNX going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank 3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

MacroGenics, Inc. (MGNX) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research